A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer

Overview of attention for article published in British Journal of Cancer, May 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 1 news outlet

patent: 5 patents

Citations

dimensions_citation: 37 Dimensions

Readers on

mendeley: 19 Mendeley

Summary News Patents Dimensions citations

So far, Altmetric has seen 5 patents that reference this research output.

Anti-FGFR2 Antibodies in Combination with Chemotherapeutic Agents in Cancer Treatment

Grant JP-7299842-B2

Japan

FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer…

Grant US-11447553-B2

United States of America

Afucosylated anti-FGFR2IIIB antibodies

Grant US-11235059-B2

United States of America

Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6…

Grant US-11091555-B2

United States of America

Anti-FGFR2 antibody combined with chemotherapeutic agent in cancer treatment

Application JP-2020520903-A

Japan